Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art review provides a historical perspective of the development of the mRSS, summarizes the performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for incorporation of the mRSS into clinical trials.

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 101685427

Journal ID (pubmed-jr-id): 45399

Journal ID (nlm-ta): J Scleroderma Relat Disord

Journal ID (iso-abbrev): J Scleroderma Relat Disord

Title: Journal of scleroderma and related disorders

ISSN (Print): 2397-1983

ISSN (Electronic): 2397-1991

Publication date Nihms-submitted: 7 February 2017

Publication date (Print): Jan-Apr 2017

Publication date PMC-release: 15 May 2017

Volume: 2

Issue: 1

Pages: 11-18

Affiliations

[1 ]University of Michigan Scleroderma Program, Ann Arbor, MI, USA

[2 ]UCLA, Los Angeles, CA, USA

[3 ]Paris Descartes University, rheumatology A dpt, Cochin Hospital, Paris, France

[4 ]Department of Medicine, McGill University Division of Rheumatology Jewish General Hospital, Montréal, Canada

[5 ]Department of Immunology and Rheumatology, University of Pécs, Hungary

[6 ]Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland

[7 ]Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany

[8 ]Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, 2Tokyo, Japan

[9 ]Department of Experimental & Clinical Medicine, Division of Rheumatology AOUC, University of Florence, Firenze, Italy

[10 ]University of Texas McGovern Medical School, Houston, TX, USA

[11 ]University of Pittsburgh, Pittsburgh, PA, USA

[12 ]University of Pennsylvania, Philadelphia, PA, USA

[13 ]Deparment of Medicine, University of Western Ontario, London, ON, Canada

[14 ]Scleroderma Research Consultants LLC, Litchfield, CT, USA

[15 ]Georgetown University, Washington DC, USA

[16 ]Division of Rheumatology, St. Vincent’s Hospital, Melbourne, Australia

[17 ]Centre for Rheumatology, Royal Free and University College London Medical School, London, UK

Author notes

Corresponding author: Dinesh Khanna, MD, MSc, Professor of Medicine, Director, University of Michigan Scleroderma Program, Division of Rheumatology/Dept. of Internal Medicine Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI 48109, khannad@ 123456med.umich.edu , Phone: 734.647.8173, Fax: 734.763.5761

Article

Accession ID: PMC5431585 Pmcid ID: PMC5431585 Pmc-uid ID: 5431585 Manuscript ID: nihpa849080

DOI: 10.5301/jsrd.5000231

PMC ID: 5431585

PubMed ID: 28516167

SO-VID: a9c7edfe-e3d5-4066-8142-a494c420531f

History

Comments

Comment on this article

scite_

Cited by 140

See all cited by

- Version 1